PHILADELPHIA – April 16, 2015 –– ERT, a leading global solutions provider for high-quality patient safety and efficacy endpoint data collection, today announced the launch of the Insights Cloud™, a suite of data analytics, visualization, and workflow applications that leverage real-time clinical trials data to provide clinical trial sponsors and CROs with actionable insights and process optimization. EXPERT Central™ - ERT's proprietary Research & Integration platform - includes an eClinical data hub for integrating and harmonizing clinical trials data from any clinical system. The integration framework includes standard adapters to leading electronic data capture (EDC) solutions such as Medidata Rave® and Oracle InForm®, and facilitates the real-time exchange of clinical trials data.
“As the clinical research industry continues to struggle with the proliferation of data silos, ERT has been evaluating how best to help our customers overcome the challenges of data fragmentation,” states Jim Corrigan, President and CEO of ERT. “Since our acquisition of eClinical Insights in 2014, we have been incorporating their innovative integration technology to support this mission, and are excited to release this first-in-class platform that provides our customers with capabilities for accessing, sharing, and integrating their clinical trials data."
By extending the proven ERT EXPERT platform with eClinical Insight’s integration technology, trial sponsors and CROs will benefit from the rapid deployment of the ERT EXPERT Central data integration layer that enables real-time data exchange between systems. The end result is comprehensive insight into investigative site and outcomes data activity across all spectrums of clinical and operational data. The ERT Insights Cloud now offers site selection, true risk-based management, enhanced performance measurement, and informed real-time decision-making.
“This is the first of many initiatives at ERT to help our customers leverage our solutions to enable data-driven trial management strategies,” said Amy Furlong, Executive Vice President, Cardiac Safety and Insights Solutions at ERT. “With the global and diverse nature of clinical trials today, the ERT Insights Cloud is the only solution that crosses the boundaries of disparate technology and disconnected teams by centralizing data, harmonizing workflow, and delivering a fully integrated business intelligence solution. In addition, with our forty plus years of experience and vast amount of current and historical site performance metrics, we are now assisting sponsors and CROs in site selection and performance management.”
ERT representatives will demonstrate the ERT Insights Cloud at the BioIT World Conference and Expo, booth #154, in Boston, MA beginning Monday, April 20.
For more information on the ERT Insights Cloud and EXPERT Central, visit here.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.